Short answer
Janux Therapeutics, Inc. (JANX) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Eric Dobmeier reappointed immediately as Class II director after resigning from Class III.
Janux Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Eric Dobmeier reappointed immediately as Class II director after resigning from Class III
- Reclassification solely rebalances director classes, not a substantive board departure
- Class II term expires at 2026 Annual Meeting versus prior Class III term expiring in 2027
- Continued Compensation Committee service and uninterrupted equity vesting and director compensation rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Janux Therapeutics, Inc. 8-K filings
Get the next JANX 8-K as it lands
Follow JANX for push alerts, or ask the research agent what this filing means.